ikt-001
ikt-001: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | Phase 3 |
Clinical Trials (1)
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)
FDA Decisions
FDA_MeetingFDA provided written response allowing the Company to transition to a single pivotal two-part adaptive Phase 3 study design for PAH.(IKT)
Frequently asked questions
Who is developing ikt-001?
ikt-001 is being developed by Inhibikase Therapeutics, Inc..
How many clinical trials involve ikt-001?
BioSniper tracks 1 clinical trial involving ikt-001.
What is ikt-001's latest FDA decision?
The most recent tracked FDA decision for ikt-001 is FDA_Meeting for FDA provided written response allowing the Company to transition to a single pivotal two-part adaptive Phase 3 study design for PAH..
Get deeper analysis on ikt-001
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis